Show brief item record

dc.contributor.authorShrestha, Binita
dc.contributor.authorWang, Lijun
dc.contributor.authorBrey, Eric M.
dc.contributor.authorUribe, Gabriela Romero
dc.contributor.authorTang, Liang
dc.date.accessioned2021-06-24T14:11:20Z
dc.date.available2021-06-24T14:11:20Z
dc.date.issued6/8/2021
dc.identifierdoi: 10.3390/pharmaceutics13060853
dc.identifier.citationPharmaceutics 13 (6): 853 (2021)
dc.identifier.urihttps://hdl.handle.net/20.500.12588/626
dc.description.abstractCancer is a heterogeneous and complex disease. Traditional cancer therapy is associated with low therapeutic index, acquired resistance, and various adverse effects. With the increasing understanding of cancer biology and technology advancements, more strategies have been exploited to optimize the therapeutic outcomes. The rapid development and application of nanomedicine have motivated this progress. Combinational regimen, for instance, has become an indispensable approach for effective cancer treatment, including the combination of chemotherapeutic agents, chemo-energy, chemo-gene, chemo-small molecules, and chemo-immunology. Additionally, smart nanoplatforms that respond to external stimuli (such as light, temperature, ultrasound, and magnetic field), and/or to internal stimuli (such as changes in pH, enzymes, hypoxia, and redox) have been extensively investigated to improve precision therapy. Smart nanoplatforms for combinational therapy have demonstrated the potential to be the next generation cancer treatment regimen. This review aims to highlight the recent advances in smart combinational therapy.
dc.titleSmart Nanoparticles for Chemo-Based Combinational Therapy
dc.date.updated2021-06-24T14:11:21Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show brief item record